A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma

METHODS: 83 patients with hepatocellular carcinoma (HCC) admitted to the interventional oncology department were randomly divided into two groups. Apatinib and camrelizumab were administered to 42 patients in group A, whereas sorafenib was administered to 41 patients in group B for three months. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qing, Li, Gengyu, Wu, Xiaoqiu, Lin, Haiying, Wu, Wanrui, Xie, Xiangpang, Zhu, Yu, Cai, Wei, Shi, Changsheng, Zhuo, Shengye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090460/
https://www.ncbi.nlm.nih.gov/pubmed/37064142
http://dx.doi.org/10.3389/fonc.2023.1136366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090460/
https://www.ncbi.nlm.nih.gov/pubmed/37064142
http://dx.doi.org/10.3389/fonc.2023.1136366

Ejemplares similares